4.8 Review

Postoperative Mortality Among Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis of Population-Based Studies

Journal

GASTROENTEROLOGY
Volume 149, Issue 4, Pages 928-937

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1053/j.gastro.2015.06.001

Keywords

Treatment; Complication; Death; Survival

Funding

  1. Canadian Institutes of Health Research Funding Source: Medline
  2. Alberta Innovates [201500359] Funding Source: researchfish

Ask authors/readers for more resources

BACKGROUND & AIMS: There have been varying reports of mortality after intestinal resection for the inflammatory bowel diseases (IBDs). We performed a systematic review and meta-analysis of population-based studies to determine postoperative mortality after intestinal resection in patients with IBD. METHODS: We searched Medline, EMBASE, and PubMed, from 1990 through 2015, to identify 18 articles and 3 abstracts reporting postoperative mortality among patients with IBD. The studies included 67,057 patients with ulcerative colitis (UC) and 75,971 patients with Crohn's disease (CD), from 15 countries. Mortality estimates stratified by emergent and elective surgeries were pooled separately for CD and UC using a random-effects model. To assess changes over time, the start year of the study was included as a continuous variable in a meta-regression model. RESULTS: In patients with UC, postoperative mortality was significantly lower among patients who underwent elective (0.7%; 95% confidence interval [CI], 0.6%-0.9%) vs emergent surgery (5.3%; 95% CI, 3.8%-7.4%). In patients with CD, postoperative mortality was significantly lower among patients who underwent elective (0.6%; 95% CI, 0.2%-1.7%) vs emergent surgery (3.6%; 95% CI, 1.8%-6.9%). Postoperative mortality did not differ for elective (P =.78) or emergent (P =.31) surgeries when patients with UC were compared with patients with CD. Postoperative mortality decreased significantly over time for patients with CD (P <.05) but not UC (P =.21). CONCLUSIONS: Based on a systematic review and meta-analysis, postoperative mortality was high after emergent, but not elective, intestinal resection in patients with UC or CD. Optimization of management strategies and more effective therapies are necessary to avoid emergent surgeries.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Letter Gastroenterology & Hepatology

Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease

Joshua Quan, Christopher Ma, Remo Panaccione, Lindsay Hracs, Nastaran Sharifi, Michelle Herauf, Ante Makovinovic, Stephanie Coward, Joseph W. Windsor, Lea Caplan, Richard J. M. Ingram, Jamil N. Kanji, Graham Tipples, Jessalyn K. Holodinsky, Charles N. Bernstein, Douglas J. Mahoney, Sasha Bernatsky, Eric Benchimol, Gilaad G. Kaplan

Article Gastroenterology & Hepatology

Multimodal Brain MRI of Deep Gray Matter Changes Associated With Inflammatory Bowel Disease

Bradley G. Goodyear, Faranak Heidari, Richard J. M. Ingram, Filomeno Cortese, Nastaran Sharifi, Gilaad G. Kaplan, Christopher Ma, Remo Panaccione, Keith A. Sharkey, Mark G. Swain

Summary: Magnetic resonance imaging revealed structural and functional changes within the brains of inflammatory bowel disease patients, in regions known to be involved in processing brain signals associated with behavioral symptoms, anxiety, pain, stress, and cognitive deficits.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme

William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes

Summary: This study provides a summary of tofacitinib safety in the treatment of ulcerative colitis. The results showed a low incidence of adverse events, with stable rates in patients treated for at least 7.8 years. The incidence rates of important safety events were generally below 2.0, except for herpes zoster.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

REMIT-UC: Real-World Effectiveness and Safety of Tofacitinib for Moderate-to-Severely Active Ulcerative Colitis A Canadian IBD Research Consortium Multicenter National Cohort Study

Christopher Ma, Remo Panaccione, Yasi Xiao, Yuvan Khandelwal, Sanjay K. Murthy, Emily C. L. Wong, Neeraj Narula, Catherine Tsai, Farhad Peerani, Marica Reise-Filteau, Brian Bressler, Samantha Y. Starkey, Dustin Loomes, Rocio Sedano, Vipul Jairath, Talat Bessissow

Summary: This Canadian multicenter cohort study evaluated the real-world effectiveness and safety of tofacitinib for the treatment of ulcerative colitis (UC). The study found that one-third of UC patients achieved clinical remission with few serious adverse events. However, half of the patients lost response with dose de-escalation, highlighting the importance of counseling patients with negative prognostic factors about the risks and benefits of continuing high doses of tofacitinib.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2023)

Article Gastroenterology & Hepatology

Hospitalization Rates for Inflammatory Bowel Disease Are Decreasing Over Time: A Population-based Cohort Study

Michael J. Buie, Stephanie Coward, Abdel-Aziz Shaheen, Jayna Holroyd-Leduc, Lindsay Hracs, Christopher Ma, Remo Panaccione, Eric Benchimol, Charles N. Bernstein, Alain Bitton, Anthony R. Otley, Jennifer L. Jones, Sanjay K. Murthy, M. Ellen Kuenzig, Juan-Nicolas Pena-Sanchez, Laura E. Targownik, Harminder Singh, Antonio Avina-Zubieta, Gilaad G. Kaplan

Summary: Recent advances in IBD management have led to a decrease in hospitalization rates for IBD-related and non-IBD-related causes. The study observed a decline in all-cause hospitalization rates as well.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey

Florence-Damilola Odufalu, Marla C. Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylanne, Allyson Sipes, Joseph C. Cappelleri, Leo J. Russo, Michelle Segovia, Sean Gardiner, Edward P. Johnson, Amy Mulvey, Remo Panaccione

Summary: This study investigated the impact of patient demographics and psychological comorbidities on disease management and health care experience in patients with ulcerative colitis, highlighting the need for better understanding and improvement of patient care.

INFLAMMATORY BOWEL DISEASES (2023)

Article Gastroenterology & Hepatology

Upadacitinib Induction and Maintenance Therapy Improves Abdominal Pain, Bowel Urgency, and Fatigue in Patients With Ulcerative Colitis: A Post Hoc Analysis of Phase 3 Data

Silvio Danese, Jacinda Tran, Geert D'Haens, David T. Rubin, Nobuo Aoyama, Wen Zhou, Dapo Ilo, Xuan Yao, Yuri Sanchez Gonzalez, Remo Panaccione

Summary: This post hoc analysis evaluated the effects of upadacitinib on fatigue, bowel urgency, and abdominal pain in patients with ulcerative colitis. The results showed that upadacitinib induction treatment significantly reduced abdominal pain and bowel urgency, and also improved fatigue symptoms.

INFLAMMATORY BOWEL DISEASES (2023)

Review Gastroenterology & Hepatology

Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials

Harris A. Ahmad, James E. East, Remo Panaccione, Simon Travis, James B. Canavan, Keith Usiskin, Michael F. Byrne

Summary: Artificial intelligence has the potential to improve clinical research in inflammatory bowel disease endoscopy. It can enhance the efficiency and accuracy of assessing endoscopic activity in patients with inflammatory bowel disease and the impact of therapeutic interventions. This review discusses the current state of endoscopic assessment in inflammatory bowel disease clinical trials, highlighting the potential for artificial intelligence to transform the current paradigm and suggesting steps for implementation. By incorporating artificial intelligence into quality evaluation and patient progress monitoring, precision endoscopy and clinical trial recruitment in inflammatory bowel disease can be advanced.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis

Remo Panaccione, Eric B. Collins, Gil Y. Melmed, Severine Vermeire, Silvio Danese, Peter D. R. Higgins, Christina S. Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang

Summary: Indirect evidence suggests that Upadacitinib may be more effective than other advanced therapies in achieving clinical response, clinical remission, and endoscopic response in patients with moderately to severely active ulcerative colitis over a one-year period, with similar safety profiles across different therapies.

CROHNS & COLITIS 360 (2023)

Article Gastroenterology & Hepatology

The Real-World Global Use of Patient-Reported Outcomes for the Care of Patients With Inflammatory Bowel Disease

Jamie M. Horrigan, Edouard Louis, Antonino Spinelli, Simon Travis, Bjorn Moum, Jessica Salwen-Deremer, Jonas Halfvarson, Remo Panaccione, Marla C. Dubinsky, Pia Munkholm, Corey A. Siegel

Summary: This study investigated the global use and barriers to using patient-reported outcomes (PROs) in clinical practice for inflammatory bowel disease (IBD). The majority of healthcare providers use PROs in clinical practice, but there are variations in which PROs are used and how they influence management. Barriers to using PROs include lack of familiarity, integration issues, and time constraints. Education about PROs and the use of an accepted set of PROs can help overcome these barriers and achieve global harmonization.

CROHNS & COLITIS 360 (2023)

Article Gastroenterology & Hepatology

Efficacy and Safety of Approximately 3 Years of Continuous Ozanimod in Moderately to Severely Active Ulcerative Colitis: Interim Analysis of the True North Open-label Extension

Silvio Danese, Remo Panaccione, Maria T. Abreu, David T. Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C. Wolf, Michael Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T. Osterman, Hsiuanlin Wu, James B. Canavan, Annkatrin Petersen, Jean-Frederic Colombel, Miguel Regueiro

Summary: This interim analysis examines the efficacy and safety of ozanimod treatment in patients with ulcerative colitis over a period of approximately 3 years. The results show that a high percentage of patients maintain clinical and mucosal efficacy during the treatment. No new safety concerns arise from long-term use of ozanimod.

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial

Marc Ferrante, Peter M. Irving, Maria T. Abreu, Jeffrey Axler, Xiang Gao, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Joana Torres, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Sofie Berg, Xiaomei Liao, Qing Zhou, Jasmina Kalabic, Brian Feagan, Remo Panaccione

Summary: This post-hoc analysis found that maintenance therapy with risankizumab can lead to durable improvement in clinical and endoscopic outcomes for patients with moderately to severely active Crohn's disease, achieving the treatment goals of durable clinical remission, endoscopic healing, and biomarker normalization.

JOURNAL OF CROHNS & COLITIS (2023)

Meeting Abstract Gastroenterology & Hepatology

Exploring duration of corticosteroid withdrawal in definitions of corticosteroid-free remission endpoints in ustekinumab clinical trials: results from the IM-UNITI, UNIFI, and SEAVUE trials

J. Panes, R. Panaccione, B. Sands, C. Gasink, C. Marano, T. Ma, T. Hoops

JOURNAL OF CROHNS & COLITIS (2023)

Article Gastroenterology & Hepatology

Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis

Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D. R. Higgins, Edward V. Loftus Jr, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hebuterne, James O. Lindsay, Qian Cao, Hiroshi Nakase, Jean-Frederic Colombel, Severine Vermeire

Summary: Upadacitinib demonstrates efficacy and safety for 16-week induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Patients without clinical response after 8 weeks' upadacitinib 45 mg induction therapy may benefit from an additional 8 weeks of therapy.

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2023)

Correction Gastroenterology & Hepatology

Tofacitinib for the Treatment of Ulcerative Colitis: An Integrated Summary of up to 7.8 Years of Safety Data from the Global Clinical Programme (Sep, jjac141, 2022)

William J. Sandborn, Geert R. D'Haens, Bruce E. Sands, Remo Panaccione, Siew C. Ng, Nervin Lawendy, Nicole Kulisek, Irene Modesto, Xiang Guo, Rajiv Mundayat, Chinyu Su, Ivana Vranic, Julian Panes

JOURNAL OF CROHNS & COLITIS (2023)

No Data Available